Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Deals

Thumbnail
December 12, 2019

Ash 2019 winners and losers

Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.

Thumbnail
December 09, 2019

Ash 2019 – Merck gets Arqule ahead of data

Arqule’s investors have done pretty nicely out of today’s buyout by Merck & Co, but might be wondering whether they could have done better still.

Article image
Vantage logo
November 04, 2019

Wright and Stryker embark on a joints venture

Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.

Article image
Vantage logo
November 01, 2019

Breaking down Beigene’s latest deal with the west

A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.

Article image
Vantage logo
October 31, 2019

One step forward, two steps back for prescription apps

Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.

Article image
Vantage logo
October 28, 2019

Another robot deal for J&J shows up lack of Verb results

Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.

Article image
Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.

Article image
Vantage logo
October 22, 2019

GTX Medical gains a new technology and loses a competitor

In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.

Article image
Vantage logo
October 21, 2019

Vindication is sweet for Seattle

Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.

Article image
Vantage logo
October 21, 2019

Bavarian’s chance to draw a line under oncology

The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.

Article image
Vantage logo
October 18, 2019

A change of the guard for the world’s biggest cancer companies

Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.